Form 4: PAVmed Inc. Director Acquires Shares

PAVmed Inc. director Michael J. Glennon acquired 13,930 shares of common stock through a restricted stock grant.

Summary

• Michael J. Glennon, a Director at PAVmed Inc., received a grant of 13,930 shares of common stock on April 2, 2026.
• These shares were granted under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock has a single vesting date of May 20, 2029, and is subject to forfeiture if the service period is not completed.
• Following this transaction, Mr. Glennon beneficially owns 21,653 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider stock grant without providing new financial or operational information that would significantly alter the investment thesis.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The grant of restricted stock aligns the director's interests with long-term shareholder value.
• The transaction indicates continued engagement and commitment from a key insider.

Negatives

• The shares are restricted and subject to forfeiture, meaning full ownership is contingent on future service.
• The grant has a long vesting period (until May 20, 2029), indicating a long-term incentive structure rather than immediate benefit.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed, posing a risk to the director's ultimate ownership.
• Future service period completion is a condition for full ownership, introducing a performance-related risk.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance or business operations. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider grants of restricted stock are common in the biotechnology and healthcare sectors, often used to attract and retain key talent and align executive interests with long-term company growth and value creation.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aligns their interests with long-term shareholder value, potentially leading to better governance and strategic decisions. However, the immediate impact on share price is minimal as it's a non-cash compensation event.
• Employees: The existence of long-term incentive plans, like the one under which this grant was made, can contribute to a positive company culture and employee retention.
• Management: The transaction confirms the ongoing compensation structure for directors, reinforcing their commitment to the company.

Next Steps

• Director Michael J. Glennon must complete the requisite service period until May 20, 2029, to fully vest in the granted shares.
• PAVmed Inc. will continue to operate under its existing business plans and strategies.

Key Dates

Keywords

PAVmed Inc., PAVM, Form 4, Insider Transaction, Restricted Stock, Equity Grant, Director, Beneficial Ownership, Securities Exchange Act